IL-17、IL-23在接受利妥昔单抗治疗的B细胞非霍奇金淋巴瘤患者中的表达
The Expression and Significance of IL-17 and IL-23 in Patients with B-cell non-Hodgkin Lymphoma Treated by RCHOP
-
摘要: 目的 检测B细胞非霍奇金淋巴瘤 (non-Hodgkin lymphoma, NHL) 患者治疗前后IL-17、IL-23表达水平的变化, 探讨IL-17、IL-23在NHL发生发展过程中的作用.方法 应用逆转录-聚合酶链式反应 (reverse transcription-polymerase chain reaction, RT-PCR) 法检测25例接受标准剂量R-CHOP方治疗68个疗程的B细胞NHL患者和20例健康对照组.结果 NHL患者初诊时和缓解时外周血中IL-17m RNA的表达水平均低于健康对照组 (P<0.05) .NHL患者缓解时与初诊时相比, IL-17m RNA的表达水平有所升高 (P<0.05) .NHL患者初诊时和缓解时外周血中IL-23m RNA的表达水平均低于健康对照组 (P<0.05) .缓解时与初诊时相比, IL-23m RNA的表达水平升高 (P<0.05) .结论 B细胞非霍奇金淋巴瘤患者接受利妥昔单抗治疗后IL-17、IL-23水平升高.IL-17、IL-23m RNA的表达与预后相关.Abstract: Objectives To detect the expression levels of IL-17 and IL-23 in peripheral blood of B-cell non-Hodgkin lymphoma patients treated by RCHOP and to study the role of IL-17 and IL-23 in NHL.Methods Twenty-five patients with B-cell NHL who achieved remission after 6 to 8 cycles of R-CHOP as a NHL group, 20 healthy volunteers were recruited as a normal control group.RT-PCR was used to detect the expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients and health volunteers.Results The expression levels of IL-17 m RNA and IL-23 m RNA in the patients with NHL before therapy and the patients with NHL who achieved remission were lower than that in the normal control group (P<0.05) .The expression levels of IL-17 m RNA and IL-23 m RNA in the patients with NHL who achieved remission were higher than that in the patients with NHL before therapy (P=0.001, P<0.05) .Conclusions IL-17 and IL-23 m RNA levels are higher after treated with R-CHOP. The expression levels of IL-17 m RNA and IL-23 m RNA in NHL patients are related with prognosis and efficacy.
-
Key words:
- Non-Hodgkin lymphoma /
- Interleukin-17 /
- Interleukin-23 /
- Rituximab /
- Prognosis
-
[1] [1]SIEGEL R L, MILLER K D, JEMAL A.Cancer statistics, 2015[J].CA Cancer J Clin, 2015, 65 (1) :5-29. [2] [2]STASICR, DELPOETAG, STIPAE, et al.Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura[J].Blood, 2007, 110 (8) :2924-2930. [3] [3]STASI R, COOPERN, DELPOETAG, et al.Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab[J].Blood, 2008, 112 (4) :1147-1150. [4] [4]SHAHRARAS, HUANGQ, MANDELINAM, et al.TH-17 cells in rheumatoid arthritis[J].Arthritis Res Ther, 2008, 10 (4) :R93. [5] [5]RACKEMK.Immunopathogenesis of multiple sclerosis[J].Ann Indian Acad Neurol, 2009, 12 (4) :215-220. [6] [6]ZHOU L, LITTMANDR.Transcriptional regulatory networks in Th17 cell differentiation[J].Curr Opin Immunol, 2009, 21 (2) :146-152. [7] [7]STARK M A, HUO Y, BURCIN T L, et al.Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17[J].Immunity, 2005, 22 (3) :285-294. [8] [8]TZANKOVA, MEIERC, HIRSCHMANNP, et al.Correlation of high numbers of intratumoral FOXP3+regulatory T cells with improved survival in germinal center like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma[J].Haematologica, 2008, 93 (2) :193-200. [9] [9]GHILARDIN, OUYANGW.Targeting the development and effector functions of TH17 cells[J].Semin Immunol, 2007, 19 (6) :383-393. [10] [10]SAKAGUCHI S.Regulatory T cells:Key controllers of immunologic self-tolerance[J].Cell, 2000, 101 (5) :455-458. [11] [11]PARK H, LIZ, YANGXO, et al.A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17[J].Nat Immunol, 2005, 6 (11) :1133-1141. [12] [12]OPPMANNB, LESLEYR, BLOMB, et al.Novel p19 protein engages IL-12p40 to form a cytokine from a cytokine, IL-23, with biological activities similar as well as distinct from IL-12[J].Immunity, 2000, 13 (5) :715-725. [13] [13]LU T, YUS, LIUY, et al.Aberrant circulating Th17 cells in patients with B-cell non-hodgkin’s lymphoma[J].PLo S One, 2016, 11 (1) :e0148044.
点击查看大图
计量
- 文章访问数: 1891
- HTML全文浏览量: 699
- PDF下载量: 30
- 被引次数: 0